Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 13/20 | 0.97 |
| ▸ | DDB1 known ✓ | Q16531 | 3/20 | 0.97 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.97 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.97 |
| ▸ | TNF | P01375 | 3/20 | 0.97 |
| ▸ | IL1B | P01584 | 3/20 | 0.97 |
| ▸ | BRD4 | O60885 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenalidomide SCHEMBL33695 | 1.00 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL33791 | 1.00 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL30876939 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192650 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29377496 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL868339 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192655 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18825 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192663 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29414335 | 0.99 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496568-B1 | POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF | NANJING CAVENDISH BIO-ENGINEERING TECH CO LTD (CN) | 2017-04-26 | — | — | EP | claimed |
| US-9371309-B2 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | CELGENE CORPORATION (US) | 2016-06-21 | — | — | US | claimed |
| US-9101620-B2 | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-08-11 | — | — | US | claimed |
| EP-2426118-B1 | Methods of making polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | CELGENE CORP (US) | 2013-01-23 | — | — | EP | claimed |
| EP-2496568-A1 | POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-09-12 | — | — | EP | claimed |
| US-20120203005-A1 | POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-08-09 | — | — | US | claimed |
| EP-2425836-A1 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | Celgene Corporation (US) | 2012-03-07 | — | — | EP | claimed |
| EP-2426118-A1 | Methods of making the polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | Celgene Corporation (US) | 2012-03-07 | — | — | EP | claimed |
| US-20120029019-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2012-02-02 | — | — | US | claimed |
| US-20120022106-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2012-01-26 | — | — | US | claimed |
| US-8058443-B2 | making crystalline lenalidomide | CELGENE CORPORATION (US) | 2011-11-15 | — | — | US | claimed |
| EP-1667682-B1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2011-11-02 | — | — | EP | claimed |
| WO-2011050590-A1 | POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2011-05-05 | — | — | WO | claimed |
| US-7855217-B2 | solid forms of lenalidomide, treating cancer, inflammatory disease, myelodysplastic syndrome, undesired angiogenesis | CELGENE CORPORATION (US) | 2010-12-21 | — | — | US | claimed |
| US-20090187023-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL))-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2009-07-23 | — | — | US | claimed |
| US-20090149499-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE) | CELGENE CORPORATION | 2009-06-11 | — | — | US | claimed |
| US-20090149500-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2009-06-11 | — | — | US | claimed |
| US-7465800-B2 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | CELGENE CORPORATION (US) | 2008-12-16 | — | — | US | claimed |
| EP-2496568-B1 | POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF | NANJING CAVENDISH BIO-ENGINEERING TECH CO LTD (CN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2011050962-A1 | ACID ADDITION SALTS OF LENALIDOMIDE | RATIOPHARM GMBH (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149500-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | HLA-DRB1, DPYD, HLA-C | CRBN 4392/4885DDB1 55/4885IKZF3 2590/4885 |
| US-20090149499-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE) | HLA-DRB1, DPYD, HLA-C | CRBN 4273/4885DDB1 53/4885IKZF3 2771/4885 |
| US-20120029019-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | HLA-DRB1, DPYD, HLA-C | CRBN 4362/4885DDB1 64/4885IKZF3 2970/4885 |
| US-20090187023-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL))-PIPERIDINE-2,6-DIONE | HLA-DRB1, DPYD, HLA-C | CRBN 4405/4885DDB1 57/4885IKZF3 2794/4885 |
| US-20120022106-A1 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | HLA-DRB1, DPYD, HLA-C | CRBN 4362/4885DDB1 64/4885IKZF3 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.